Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/35361913http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/35361913http://www.w3.org/2000/01/rdf-schema#comment"Type III interferons (IFNs) play an important role in respiratory viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This study aimed to determine whether the expression of serum type III IFNs predicted disease severity among patients with the coronavirus disease (COVID-19). A retrospective cohort study was conducted of patients admitted to a single hospital between March 21, 2020, and March 31, 2021. Patients were divided into mild to moderate I (MM) and moderate II to severe (MS) groups based on the COVID-19 severity classification developed by the Japanese Ministry of Health, Labor and Welfare. A total of 257 patients were included in the analysis. Human interleukin-28A (IL-28A/IFN-λ2) expression was significantly lower, and interleukin (IL)-6 expression was significantly higher in the MS group than in the MM group (both p < 0.001). In addition, IL-28A/IFN-λ2 was statistically significantly inversely correlated with the time from disease onset to negative SARS-CoV-2 PCR results (p = 0.049). Multivariable logistic regression analysis showed that IL-28A/IFN-λ2 was an independent predictor of disease severity (p = 0.021). The low expression of IL-28A/IFN-λ2 may serve as a serum biomarker that predicts the severity of COVID-19, possibly through the mechanism of delayed viral elimination."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.org/dc/terms/identifier"doi:10.1038/s41598-022-09544-8"xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Inoue H."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Goto Y."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Ikeda H."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Sato Y."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Suzuki S."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Sato H."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Tanaka A."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Uchida Y."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Kawahara T."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Fukuda Y."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Homma T."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Akimoto K."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Sagara H."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Ebato T."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Suganuma H."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Onitsuka C."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/author"Mikuni H."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/date"2022"xsd:gYear
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/name"Sci Rep"xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/pages"5458"xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/title"Serum IL-28A/IFN-lambda2 is linked to disease severity of COVID-19."xsd:string
http://purl.uniprot.org/citations/35361913http://purl.uniprot.org/core/volume"12"xsd:string
▶